AAOMS Annual Meeting

The FDA approved Symbicort Inhalation Aerosol 80/4.5 for the treatment for the treatment of asthma in pediatric patients aged 6 to 12 years.

The FDA has approved AirDuo RespiClick and ArmonAir RespiClick for the treatment of adolescent and adult patients with asthma.

The FDA has approved AirDuo RespiClick and ArmonAir RespiClick for the treatment of adolescent and adult patients with asthma.

The FDA has approved AirDuo RespiClick and ArmonAir RespiClick for the treatment of adolescent and adult patients with asthma.

The FDA has approved Trulance (plecanatide) for the treatment of chronic idiopathic constipation in adults.

The FDA has approved Trulance (plecanatide) for the treatment of chronic idiopathic constipation in adults.

The FDA has approved Trulance (plecanatide) for the treatment of chronic idiopathic constipation in adults.

The FDA has approved Rhofade (oxymetazoline hydrochloride) cream, 1%, for the topical treatment of persistent facial erythema associated with rosacea.

The FDA has approved Rhofade (oxymetazoline hydrochloride) cream, 1%, for the topical treatment of persistent facial erythema associated with rosacea.

The FDA has approved Rhofade (oxymetazoline hydrochloride) cream, 1%, for the topical treatment of persistent facial erythema associated with rosacea.